Already Closing In On Imbruvica With Brukinsa, BeiGene Sets Its Sights On Another Hematology Blockbuster
BeiGene is seeing rapid growth thanks to Brukinsa’s head-to-head superiority in CLL to the leading BTK inhibitor, Imbruvica, and now the company aims to repeat that feat by taking on another blood cancer big-hitter, Venclexta.
You may also be interested in...
The Swiss drug maker’s decision to give back rights to tislelizumab means BeiGene goes without the potentially $1.55bn in milestone payments the companies had agreed to in early 2021.
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.